Skip to main content
. Author manuscript; available in PMC: 2021 Jul 16.
Published in final edited form as: Clin Cancer Res. 2020 Jan 29;26(10):2318–2326. doi: 10.1158/1078-0432.CCR-19-3624

Table 3:

Common Treatment Related Adverse Events With at Least 5% Incidence in Study Population

Adverse Events No.(%) of patients (N=58) Cohort A1 (N=14) Cohort A2 (N=10) Cohort B1 (N=19) Cohort B2 (N=16)
Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
Lymphocyte count decreased 38 (65.5) 6 1 5 3 7 3 6 7
Anemia 20 (34.5) 3 2 6 6 3
Fatigue 10 (17.2) 1 2 7
Platelet count decreased 10 (17.2) 2 2 6
Rash 9 (15.5) 3 3 3
Nausea 7 (12.1) 1 3 2 1
Pruritus 7 (12.1) 2 3 2
AST increased 6 (10.3) 1 1 4
Vomiting 6 (10.3) 1 2 3
White blood cell decreased 6 (10.3) 1 2 1 2
Hypoalbuminemia 6 (10.3) 6
Hyponatremia 6 (10.3) 1 3 2
Diarrhea 5 (8.6) 1 3 2
Fever 5 (8.6) 1 1 1 2
Anorexia 4 (6.9) 1 3
Neutrophil count decreased 3 (5.2) 2 1
Hypothyroidism 3 (5.2) 1 1 1